YoCrunch yogurts recalled for possible plastic pieces in toppers
The company said all flavors and sizes of YoCrunch products 'currently in-market' are subject to the recall.
Advertisement
The details of the various types of recalled yogurt products and their expiration dates were listed in Danone's recall notice posted Monday on the Food and Drug Administration's website. The expiration dates range from this month to dates in September, depending on the specific product.
Danone said in a press release it 'takes every consumer experience seriously and is initiating this voluntary recall in line with its commitment to product safety quality and consumer safety.'
The recall was spurred by some consumers saying they discovered plastic pieces within the toppers of the YoCrunch products, the FDA recall notice said.
4 Recalled boxes of YoCrunch yogurt with Oreo and M&Ms.
FDA
Advertisement
4 The company said all flavors and sizes of YoCrunch products 'currently in-market' are subject to the recall.
The clear plastic pieces, which could be sharp and be between 7-25 millimeters long in some cases, 'have the potential to cause choking,' per the notice.
The possible presence of the plastic pieces is 'isolated only to the separately packaged topper' that comes with the YoCrunch yogurts, the company said.
Advertisement
The dome toppers of the recalled yogurts hold toppings like Oreos, candy, cookie dough and granola, according to the FDA recall notice.
To be safe, the recalled YoCrunch yogurt products should still not be eaten, according to the recall notice. They should be thrown in the trash, Danone said on its website.
Customers can get in touch with the YoCrunch Consumer Care Line about getting their money back for any affected yogurt products, Danone said.
Sales of the recalled yogurts occurred at retailers across the country.
Advertisement
4 The dome toppers of the recalled yogurts hold toppings like Oreos, candy, cookie dough and granola, according to the FDA recall notice.
4 To be safe, the recalled YoCrunch yogurt products should still not be eaten, according to the recall notice.
Danone is 'working swiftly with retail partners to remove the impacted product from shelves, while it works to address the issue and bring back the YoCrunch products so many people enjoy,' according to the company.
FOX Business reached out to Danone for comment.
Danone U.S.'s parent company has owned YoCrunch for nearly twelve years, having purchased the brand in 2013, according to reports. The brand itself has been around for over three decades.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
12 minutes ago
- The Hill
FDA reverses ban on sale of Juul e-cigarettes
The Food and Drug Administration has authorized Juul Labs to keep its e-cigarettes on the market, a major reversal after the agency completely banned the company's products in 2022. The agency said Thursday it will allow the sale of Juul's original e-cigarette device as well as refill cartridges in tobacco and menthol flavors. The move followed 'an extensive scientific review' that showed the benefit to adult smokers outweighed the risk to young people or adults who don't smoke. FDA said Juul submitted evidence showing high rates of adults completely switched from cigarettes to either the tobacco- or menthol-flavored Juul products. 'While today's actions permit these specific e-cigarette products to be legally marketed in the U.S. to adults 21 and older, it does not mean these tobacco products are safe, nor are they FDA approved,' the agency said. FDA's decision marks the latest chapter for a company so popular it was once synonymous with vaping. But as more young people began using its fruit and candy-flavored products, federal scrutiny grew. Juul has denied allegations that it marketed its e-cigarettes to children and teens. The FDA in 2022 announced a ban on the sale of Juul e-cigarettes nationwide, saying the company did not prove that keeping its products on the market 'would be appropriate for the protection of the public health.' The agency suspended the order about two weeks later to conduct an internal review of 'scientific issues' in the company's application. Despite the pause, FDA's actions nearly bankrupted the company. It also subsequently paid $1.7 million billion to resolve thousands of lawsuits alleging the company aggressively marketed its e-cigarettes to young people and fueled a vaping crisis. The FDA considered Juul's appeal for two years and in 2024 formally rescinded the ban, putting the company's application back under scientific review. All electronic cigarette products are required by law to have FDA authorization to be legally marketed, and the companies must submit scientific evidence of public health benefits. 'Today's FDA authorization of JUUL products marks an important step toward making the cigarette obsolete,' K.C. Crosthwaite, Juul Labs' CEO said in a statement. 'We strongly support FDA's role in regulating tobacco and nicotine products,' Crosthwaite continued. 'Americans who use nicotine deserve an orderly, reliable market in which they can confidently choose from a wide array of smokefree nicotine products that are high-quality, innovative, backed by rigorous research, made in FDA-inspected manufacturing facilities, and marketed and sold responsibly.' Still, Juul is no longer the juggernaut it once was and has lost significant market share amid rising competition, including from e-cigarettes illegally imported from China. But anti-tobacco groups said they were dismayed by FDA's decision, saying it risks a reversal of recent progress in reducing youth e-cigarette use. 'It is a big step in the wrong direction to authorize sales of the product that was responsible for this public health crisis in the first place,' said Yolonda Richardson, president and CEO of the Campaign for Tobacco-Free Kids. 'There is no question that this crisis was driven by Juul's sleek, easy-to-hide products, which were sold in enticing flavors, including menthol, were marketed in ways that appeal to kids and delivered massive doses of nicotine that can quickly addict kids,' Richardson added. The American Lung Association (ALA) similarly blamed Juul for the spike in youth vaping. 'This is a serious misstep,' Ranjana Caple, senior manager of federal advocacy for ALA said in a statement. 'Juul is responsible for the youth vaping epidemic, and its products have hooked a generation of kids on nicotine. Authorizing these products signal a stunning failure to protect public health.'
Cosmopolitan
13 minutes ago
- Cosmopolitan
Skinvive Injectable Review: Cost, Results, and More
I've struggled with dry skin for as long as I can remember. As a kid, I dealt with painful eczema that burned. In middle school, my scalp was so dry and flaky that I'd coat my hair in oil and sleep in a shower cap. Now in my 20s, my face is constantly thirsty no matter how many layers of skincare I slather on. I've tried every face mist, buttery moisturizer, and hydrating serum out there. And while skincare definitely helps support my skin barrier and offers temporary relief, it's not a heal-all solution for the chronic dryness I've endured my entire life. So when I heard about Skinvive, an injectable moisturizer that's basically like a supercharged hydrator in a syringe, I was immediately intrugued. As a filler/botox/injectable virgin, I was a bit hesitant about the treatment. But after years of dealing with dry skin, I was ready to try anything. Keep reading for everything you need to know about Skinvive, including what it is, how much it costs, what results to expect, and my honest experience four months post-treatment. Plus, I tapped expert insight from plastic surgeon David Shafer, MD, for his insights too. Skinvive is the first FDA-approved hyaluronic acid microdroplet injectable. For your skin, it works to improve hydration from within, as well as smooth skin texture and increase luminosity. 'Skinvive is injected right underneath the top layer of the skin to act as an instant hydrator," says Dr. Shafer. It's injected into several spots across your cheeks in a grid-like pattern using a tiny needle. 'It upregulates the aquaporin channels, which are the connections between cells that help promote water and moisture balance in the skin, creating a more hydrated, moisture-rich environment,' he explains. While Skinvive is packed with hyaluronic acid for hydration, it goes beyond just quenching dry skin. 'Skinvive helps reduce fine lines and wrinkles, improves texture, and gives the skin a smoother, more luminous appearance,' says Dr. Shafer. After one session of Skinvive, patients can expect the following results: I personally noticed the hydration benefit more than anything else (though I'm not exactly the target demographic for fine lines just yet). Not only is my skin no longer overly dry or tight, but I also don't need to use as much moisturizer or serum as I used to. Plus, my makeup goes on way smoother thanks to my plump and hydrated face. It takes about three to four weeks to see the full effects of Skinvive. 'You're waiting for that hydration to kick in via the boost of those aquaporin channels,' says Dr. Shafer. 'Once it starts working, the effects can last a good three to six months.' It wasn't something I noticed overnight, but about a month after my treatment, I thought to myself wait, my skin hasn't flaked or itched in weeks. Yes, Skinvive is perfectly safe to get alongside Botox and fillers. 'It's a natural add-on for patients already getting injectables,' says Dr. Shafer. 'It's not a filler, and it's not Botox—it's a whole new category of treatment. It's an injectable skin hydrator.' One isn't necessarily better than the other, they're just different. 'They both involve injections, but filler adds volume and structure to the skin, while Skinvive adds hydration,' explains Dr. Shafer. The treatment process is similar, but the effects serve different skin goals. If you want to combat dryness, Skinvive is the best option here. Price: Skinvive injections start at around $750 per treatment. It's definitely not a budget-friendly alternative to moisturizer, but the cost is on par with many traditional filler and injectable appointments. Soreness: I felt some discomfort during the treatment, but I had numbing cream on, so it was tolerable. As someone who's never had anything injected into their face (and who's even scared of flu shots), the anxiety leading up to my appointment was worse than the actual pain. The treatment itself took less than ten minutes, and the only side effects I experienced were some swelling and tenderness on my cheeks for about a day following. Overall, Skinvive is definitely worth it if you have super dry skin that no moisturizer or product can fully quench, especially in the winter months. If you're on the oilier side, it's not a must-have, but it could be a nice way to support and hydrate your skin barrier from the inside, without needing to layer on extra creams, serums, and moisturizers. It's also been a surprising win for my acne-prone skin. Since I'm not loading up on as many hydrating products, I've noticed fewer breakouts overall. Looking back at old selfies, my skin was definitely more congested and I broke out more frequently before Skinvive. Plus, it's a really nice skin-smoother if you're dealing with uneven texture or fine lines. Jasmine Hyman is the assistant beauty editor at Cosmopolitan, where she covers everything in the skincare space from sunscreen to serums. For this story, she got a Skinvive treatment to see the results first-hand, and also spoke with Dr. Shafer for all his insight on the injection. Jasmine Hyman is the Assistant Beauty Editor at Cosmopolitan, where she writes about the latest beauty trends and must-have products. Her most prized beauty possessions are a meticulous skincare routine and salon blowouts. You'll also likely find her in bed reading a good book or endlessly scrolling TikTok (spoiler: it's usually the latter) while listening to Harry Styles' entire discography on repeat. Follow her on Insta to be inundated with pictures of her meals.
Yahoo
43 minutes ago
- Yahoo
The Final Countdown for New CMS Glycemic Measures: Glytec Prepares Hospitals and Health Systems with Proven, FDA-Cleared Technology Platform
167 Days to Prepare for the New Federal Reporting Requirements for Hypo- and Hyperglycemia BOSTON, July 17, 2025 /PRNewswire/ -- Glytec is the leading provider of an AI-powered technology platform for diabetes and related conditions, including its FDA-cleared Glucommander® EHR-integrated solution for inpatient glycemic management. Today, Glytec reinforced its commitment to supporting U.S. hospitals in preparation for the upcoming Centers for Medicare & Medicaid Services (CMS) mandate on inpatient glycemic control reporting. With the measurement period set to begin on January 1, 2026, and just 167 days remaining, now is an important time for hospitals to begin preparing. Equipping teams with the right tools, workflows, and data systems can help ensure readiness for these critical requirements—and avoid potential reductions in Medicare reimbursement starting in fiscal year 2028. Under the new mandate, CMS will require reporting of both severe hypoglycemia (blood glucose <40 mg/dL) and severe hyperglycemia (blood glucose >300 mg/dL) as electronic clinical quality measures (eCQMs). These measures apply to nearly 40% of hospitalized patients who experience dysglycemia during their stay. "CMS is creating focus and awareness around inpatient diabetes care," said Patrick Cua, CEO of Glytec. "This will help drive improved patient care and patient safety, but hospitals also have revenue to gain via reduced length of stay and cost avoidance through reduced hypoglycemia, lower testing costs, and improved workflows. Glytec's platform is purpose-built to lead hospitals through this transition safely and to continue to innovate around diabetes workflows to drive better patient care and overall economics for healthcare stakeholders." The new CMS reporting mandate is driven in part by the increasing prevalence of diabetes and its associated complications, which place a significant burden on healthcare systems, payors, and individual lives. More than one-third of hospitalized patients require insulin therapy to manage elevated blood glucose levels during their stay [1]. Each year, more than 2 million patients experience adverse events in the hospital related to hypoglycemia—events that, according to the Agency for Healthcare Research and Quality (AHRQ), contribute to over $8 billion in costs and are associated with increased length of stay and higher readmission rates. Despite the widespread impact of glycemic events, nearly one-third of hospitals do not track glucose management metrics, and 59% lack automated methods to collect data on rates of hyperglycemia and hypoglycemia [2]. In response, some institutions have developed internal solutions, which, while well-intentioned, may introduce challenges related to clinical oversight, regulatory alignment, and the safe management of a high-risk therapy like insulin. Technology Built for Clinical Excellence and Return on Investment The Glytec Technology Platform, leveraged by over 400 hospitals, manages complex, high-impact workflows—from hospital to home—with proven results and AI-driven intelligence. It is built on over 100 patents, 100 clinical publications, 16 years of experience, and 50+ billion data points. As an FDA-cleared platform, Glytec provides: Industry superior insulin dosing algorithms with ongoing clinical validation, monitoring, and venture-backed investment Real-time dashboards aligned with CMS reporting requirements Turn-key EHR integration, enhanced cybersecurity, and reducing IT burden and overhead Freedom to operate across the breadth of Glytec's 100+ patented algorithms, workflows, and other intellectual property. In-House Insulin Tools Fall Short Some hospitals have explored building their own in-house insulin calculators to manage glycemia, but studies and real-world feedback reveal that these solutions: Lack clinical validation, scalability, and rigor of FDA-cleared solutions Can introduce user interface challenges and omit clinical guardrails that contribute to dosing errors and patient harm Require ongoing maintenance and investment that cannot keep pace with dedicated venture-backed technology companies, and Divert critical IT staff from broader strategic hospital technology objectives 167 Days and Counting to Get It Right The countdown is on. As the CMS mandate nears, hospitals must choose partners to deliver speed, safety, and scale, and avoid the cost, delay, and proven lower outcomes of risky non-regulated approaches. About Glytec Glytec's industry-leading technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay, and optimizing clinical workflows. Its flagship product, Glucommander®—the first-ever FDA-cleared cloud-based insulin management software—integrates seamlessly with EMRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and AI-driven analytics. Supported by over 100 patents and 100 peer-reviewed publications, Glytec is dedicated to improving care from hospital to home. For more information, visit or follow Glytec on LinkedIn. Media Contact: Public RelationsGlytecPR@ References: Umpierrez GE, et al. Journal of Clinical Endocrinology & Metabolism, 87(3), 978–982. (March 2002). Cook CB, et al. Endocrine Practice, 16(2), 219–230. (March 2010). View original content to download multimedia: SOURCE Glytec, LLC
